life sciences technologies
Aktiia announced an oversubscribed $42 million Series B round, and Basil Systems secured $11.5 million in funding.
The funds will be used to advance Insilico's drug pipeline and lab, which automates the research and development process, and refine its AI-enabled models and algorithms.